dr. mark ware
DESCRIPTION
TRANSCRIPT
![Page 1: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/1.jpg)
Introduction to the Endocannabinoid System
Dr Mark A. Ware MD MRCP MScAlan Edwards Pain Management Unit
McGill UniversityMontreal, Quebec, Canada
![Page 2: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/2.jpg)
Learning objectives
• Review components and role of endocannabinoid system (ECS)
• Summarize pharmacological strategies to harness ECS
![Page 3: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/3.jpg)
1. Mack A & Joy J., 2001.2. Notcutt W., 2004.
Cannabinoids and Opioids: A Historical Perspective
500 BC 1522 1804
1900’s
19701817
1988
1900’s
1964 1998
1975
Earliest known reference for opium-based elixir
3000 BC
First evidence of medicinal use in China
1800’s
W.B. O’Shaughnessey’swork popularizes cannabis use
Medicinal cannabis use declines
Paracelsus reference to “laudanum”, opium-based elixir, as a potent painkiller
1804: Morphine extracted from opium poppy plant
1817: Morphine first marketed in Germany as analgesic
Morphine analogs synthesized: 1874: Diacetylmorphine (heroin)1900s: codeine, dihydromorphine, oxycodone, pethidine, oxymorphone
1970s: Discovery of opioid receptors – µ (mu), к (kappa), δ (delta)
1975: Discovery of endogenous opioid peptides - endorphins
9-THC identified as main psychoactive agent in Cannabis sativa plant
1988: CB1 receptor identified.1990: CB1 receptor cloned1992: Anandamide discovered, CB2 receptor identified1993: CB2 receptor cloned1998: Endogenous cannabinoid ligands shown to be analgesic
1874
Cannabinoids
Opioids
![Page 4: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/4.jpg)
![Page 5: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/5.jpg)
Source: Health Canada January 2013
![Page 6: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/6.jpg)
Cannabinoid mechanisms
![Page 7: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/7.jpg)
Peripheral CB1 receptors
![Page 8: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/8.jpg)
1. Cappendijk S., 2010.2. Hanks G et al., 2003.
3. Mackie K., 2006.
Mechanisms Of ActionCannabinoidsOpioids
![Page 9: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/9.jpg)
Endocannabinoid regulation
![Page 10: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/10.jpg)
Metabolic pathways of endocannabinoids
![Page 11: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/11.jpg)
Cannabinoids as immune modulators
Nature Rev Drug Disc 2008;7:438-455
![Page 12: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/12.jpg)
Harnessing the cannabinoid system
• Exogenous compounds– Phytocannabinoids
• THC, CBD, combinations– Synthetic cannabinoids
• Nabilone
• Endogenous manipulation• FAAH inhibitors• MAGL, DAGL inhibitors
• Receptor targets– CB1, CB2, TRPV1, PPAR, 5-HT, other…
![Page 13: Dr. Mark Ware](https://reader033.vdocuments.net/reader033/viewer/2022061213/54973328b47959424d8b51aa/html5/thumbnails/13.jpg)
Some new approaches• Novel THC formulations
– Oral THC preparations– Microspheres– Topical delivery– Buccal mucoadhesive preparations– Portable vapourizers/aerosols– Rectal administration
• Therapies that increase endocannabinoid levels– Running– Osteopathic manipulation